The Technical Analyst
Black Diamond [BDTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Black Diamond Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.99% $5.11
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 264.28 mill |
| EPS: | -1.880 |
| P/E: | -2.72 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 51.72 mill |
| Avg Daily Volume: | 0.651 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.72 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.46x |
| Company: PE -2.72 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.704 (-86.23%) $-4.41 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.71 - 5.51 ( +/- 7.87%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Campbell Shannon | Buy | 61 100 | Stock Option (Right to Buy) |
| 2024-04-10 | Raman Prakash | Buy | 61 100 | Stock Option (Right to Buy) |
| 2024-04-10 | Campbell Shannon | Buy | 0 | |
| 2024-04-10 | Raman Prakash | Buy | 0 | |
| 2024-03-15 | Behbahani Ali | Buy | 3 166 | Common Stock |
| INSIDER POWER |
|---|
| 98.85 |
| Last 97 transactions |
| Buy: 11 965 700 | Sell: 275 000 |
Forecast:
16:00 - $5.12
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.12
Forecast 2: 16:00 - $5.12
Forecast 3: 16:00 - $5.12
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.11 (0.99% ) |
| Volume | 0.233 mill |
| Avg. Vol. | 0.651 mill |
| % of Avg. Vol | 35.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BDTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.43 | N/A | Active |
|---|
BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 16:05:00 - Press Release
Black Diamond Therapeutics Announces Presentations At The 2024 American Society Of Clinical Oncology (asco) Annual Meeting
Cambridge, mass., april 24, 2024 (globe newswire) -- black diamond therapeutics, inc. (nasdaq: bdtx), a clinical-stage oncology company developing masterkey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 asco annual meeting, taking place may 31 – june 4 in chicago, il. the two poster presentations describe data for bdtx-1535 in patients with recurrent glioblastoma (gbm) across two clinical trials: a phase 1 dose escalation trial, for which topline data were released in december 2023, and a phase 0/1 “trigger” (“window of opportunity”) trial conducted as an investigator sponsored trial at the ivy brain tumor center (nct06072586).
2024-04-11 08:00:00 - Press Release
Black Diamond Therapeutics Announces Changes To Board Of Directors
Cambridge, mass., april 11, 2024 (globe newswire) -- black diamond therapeutics, inc. (nasdaq: bdtx), a clinical-stage oncology company developing masterkey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans shannon campbell and prakash raman, ph.d., have been appointed to the company's board of directors. the company also announced that wendy dixon, ph.d., and alex mayweg, ph.d., have stepped down as members of its board of directors. these changes became effective as of april 10, 2024.
2024-04-07 18:00:00 - Press Release
Black Diamond Therapeutics Presents Novel Real-world Evidence Of The Evolving Egfr Mutation Landscape In Nsclc And The Opportunity For Bdtx-1535 In An Oral Presentation At The 2024 American Association Of Cancer Research Annual Meeting
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with egfrm nsclc emerging data show non-classical egfr mutations can be co-expressed with the classical l858r mutation, a setting characterized by shorter duration of response to osimertinib bdtx-1535 profile differentiated as the most advanced fourth-generation oral tki in clinical development addressing the full spectrum of classical, non-classical, and c797s resistance egfr mutations cambridge, mass., april 07, 2024 (globe newswire) -- black diamond therapeutics, inc. (nasdaq: bdtx), a clinical-stage oncology company developing masterkey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (egfr) mutation landscape in non-small cell lung cancer (nsclc), and the potential of bdtx-1535 to address a broader range of mutations compared to existing therapies.
2024-04-03 08:00:00 - Press Release
Black Diamond Therapeutics To Participate In Upcoming Investor Conferences
Cambridge, mass. and new york, april 03, 2024 (globe newswire) -- black diamond therapeutics, inc. (nasdaq: bdtx), a clinical-stage oncology company developing masterkey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. presentation details with president and chief executive officer, mark velleca, m.d., ph.d., are as follows:
2024-03-12 08:00:00 - Press Release
Black Diamond Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
Cambridge, mass., march 12, 2024 (globe newswire) -- black diamond therapeutics, inc. (nasdaq: bdtx), a clinical-stage oncology company focused on the development of masterkey therapies to treat patients with genetically defined tumors, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
Latest News
2024-04-25 10:56:05 - Zacks Investment Research
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Black Diamond (BDTX) points to a 153% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-04-15 13:01:16 - Zacks Investment Research
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-04-08 10:56:05 - Zacks Investment Research
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-22 10:55:21 - Zacks Investment Research
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-12 17:21:02 - Seeking Alpha
Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company plans to initiate enrollments for expansion cohorts and seek FDA feedback for additional studies on various doses of BDTX-1535.
2023-11-07 08:00:00 - GlobeNewsWire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats during two upcoming investor conferences:
2023-10-04 12:14:00 - GlobeNewsWire
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023. The three poster presentations include initial dose escalation data from the Company's Phase 1 clinical trial of BDTX-1535 in non-small cell lung cancer (NSCLC), the study design of this ongoing Phase 1 clinical trial, and preclinical data for BDTX-4933.
2023-09-05 08:00:00 - GlobeNewsWire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that company management will participate in three upcoming investor conferences:
2023-06-29 17:48:00 - The Motley Fool
Why Shares of Black Diamond Therapeutics Skyrocketed This Week
Lung cancer is the deadliest form of cancer in the U.S. Black Diamond Therapeutics' NSCLC therapy is in early trials. The pharmaceutical company used the positive news to raise funds through a stock sale.
2023-06-27 11:56:05 - Proactive Investors
Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activity
Black Diamond Therapeutics Inc shares doubled after it saw positive initial dose escalation data from a study demonstrating the anti-tumor activity of BDTX-1535 in non-small cell lung (NSCL) cancer patients. The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCL cancer patients with both acquired resistance and intrinsic driver epidermal growth factor receptor (EGFR) mutations.